Maxim Group Begins Coverage on Alterity Therapeutics (NASDAQ:ATHE)

Stock analysts at Maxim Group started coverage on shares of Alterity Therapeutics (NASDAQ:ATHE) in a research report issued on Thursday, MarketBeat.com reports. The brokerage set a “buy” rating and a $8.00 price target on the stock. Maxim Group’s price target would suggest a potential upside of 233.33% from the stock’s previous close.

Alterity Therapeutics Price Performance

Shares of NASDAQ ATHE opened at $2.40 on Thursday. The stock has a fifty day simple moving average of $1.36 and a two-hundred day simple moving average of $1.51. Alterity Therapeutics has a 1-year low of $1.00 and a 1-year high of $3.25.

Alterity Therapeutics Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.